Your browser doesn't support javascript.
loading
Safety and efficacy of adjuvant subcutaneous trastuzumab in human epidermal growth factor receptor 2-positive early breast cancer: Final results of the SafeHER study.
Gligorov, Joseph; Pivot, Xavier; Ataseven, Beyhan; De Laurentiis, Michelino; Jung, Kyung Hae; Manikhas, Alexey; Abdel Azim, Hamdy; Gupta, Kushagra; Alexandrou, Ari; Herraez-Baranda, Luis; Tosti, Nadia; Restuccia, Eleonora.
Afiliação
  • Gligorov J; Institut Universitaire de Cancérologie AP-HP Sorbonne Université, Alliance Pour la Recherche en Cancérologie, Inserm U938, Paris, France. Electronic address: joseph.gligorov@aphp.fr.
  • Pivot X; ICANS, Strasbourg, France.
  • Ataseven B; Department of Gynecology and Gynecologic Oncology, Kliniken Essen-Mitte, Essen, Germany; Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Munich, Germany.
  • De Laurentiis M; Division of Breast Oncology, Istituto Nazionale Tumori, IRCCS, Fondazione G. Pascale, Naples, Italy.
  • Jung KH; Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
  • Manikhas A; Oncology Hospital of St. Petersburg, St. Petersburg, Russia.
  • Abdel Azim H; Clinical Oncology Department, Cairo University, Cairo, Egypt.
  • Gupta K; IQVIA RDS India Pvt Ltd, Bangalore, India.
  • Alexandrou A; F. Hoffmann-La Roche Ltd., Welwyn, United Kingdom.
  • Herraez-Baranda L; F. Hoffmann-La Roche Ltd., Basel, Switzerland.
  • Tosti N; F. Hoffmann-La Roche Ltd., Basel, Switzerland.
  • Restuccia E; F. Hoffmann-La Roche Ltd., Basel, Switzerland.
Breast ; 64: 151-158, 2022 Aug.
Article em En | MEDLINE | ID: mdl-35487845

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama Tipo de estudo: Clinical_trials / Prognostic_studies / Risk_factors_studies Limite: Female / Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama Tipo de estudo: Clinical_trials / Prognostic_studies / Risk_factors_studies Limite: Female / Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article